(Q35777411)

10 August 2017

1 reference

title

Achieving lipid goals in Europe: how large is the treatment gap? (English)

1 reference

10 August 2017

Peter Schwandt

1

1 reference

PubMed ID

15151488

10 August 2017

Adrian J B Brady

series ordinal

2

1 reference

10 August 2017

1 May 2004

1 reference

Expert Review of Cardiovascular Therapy

10 August 2017

1 reference

10 August 2017

2

1 reference

10 August 2017

3

1 reference

10 August 2017

431-449

1 reference

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

10 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Low prevalence of lipid lowering drug use in older men with established coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Secondary prevention of hypercholesterolaemia: results of an audit conducted in South Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Coronary heart disease in the statin and aspirin era: are results of clinical trials being put into practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Secondary prevention in 24, 431 patients with coronary heart disease: survey in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Use of statins in the secondary prevention of coronary heart disease: is treatment equitable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Prevalence and management of coronary heart disease in primary care: population-based cross-sectional study using a disease register

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Growth in use of statins after trials is not targeted to most appropriate patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Use of secondary preventive drugs in patients with acute coronary syndromes treated medically or with coronary angioplasty: results from the nationwide French PREVENIR survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Lipid-lowering medication for secondary prevention of coronary heart disease in a German outpatient population: the gap between treatment guidelines and real life treatment patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Lipid-lowering therapy and cholesterol levels following acute myocardial infarction: a German study of 5361 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Trends in total and high density lipoprotein cholesterol and their determinants in The Netherlands between 1993 and 1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Time trends in lipid lowering drug use in The Netherlands. Has the backlog of candidates for treatment been eliminated?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Undertreatment of hypercholesterolaemia: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

High prevalence and suboptimal treatment of risk factors in Greek coronary patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Under Treatment with Lipid-Lowering Drugs of High-Risk Coronary Heart Disease Patients of the GENICA Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

[New data on secondary prevention of myocardial infarction in Spain. Results of the PREVESE II study].

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Lack of adherence to lipid-lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Trends in lipid levels and hypercholesterolemia in hypertensive and normotensive finnish adults from 1982 to 1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

DoH explains thinking behind national service framework for coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Gap between guidelines and management of patients with acute coronary syndrome without persistent ST elevation. Finnish prospective follow-up survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Medical treatment and secondary prevention of coronary heart disease in general practice in Iceland

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Blood pressure and other cardiovascular risk factors among treated hypertensives in Swedish primary health care

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Determinants of appropriate lipid management in patients with ischaemic heart disease. Cracovian Program for Secondary Prevention of Ischaemic Heart Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Variations and increase in use of statins across Europe: data from administrative databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

The prevention education program (PEP). A prospective study of the efficacy of family-oriented life style modification in the reduction of cardiovascular risk and disease: design and baseline data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Beyond lipid lowering: the role of statins in vascular protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

A strategy to reduce cardiovascular disease by more than 80%

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE)**Further information about the project, along with a complete list

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.3.431

21 January 2018

Identifiers

DOI

10.1586/14779072.2.3.431

1 reference

10 August 2017

1 reference

PubMed ID

15151488